SIBIA NEUROSCIENCES
Similar Organizations
CHS Business Associates LLC
CHS Business Associates LLC is a Biotechnology company.
Gamera Bioscience
Gamera Bioscience is a Biotechnology company.
Triton Biosciences
Triton Biosciences is a Biotechnology company.
More informations about "SIBIA Neurosciences"
Sibia Neurosciences, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Sibia Neurosciences, Inc. with its drug pipeline, therapeutic area, technology platform, 37 literature, Drug:SP-650003, S-1663, SIB-1848, SIB-3182.See details»
SIBIA Neurosciences - Crunchbase Company Profile & Funding
Organization. SIBIA Neurosciences . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. About. SIBIA Neurosciences is a Biotechnology company. Private; โฆSee details»
SIBIA Neurosciences - Products, Competitors, Financials, โฆ
SIBIA Neurosciences, founded in 1981, is engaged in the discovery and development of novel small molecule therapeutics for the treatment of neurodegenerative, neuropsychiatric and โฆSee details»
S-1663 - Drug Targets, Indications, Patents - Synapse
S-1663: a Nicotinic receptors agonists Drug, Initially developed by Sibia Neurosciences, Inc., Now, its global highest R&D status is Pending, Mechanism: Nicotinic receptors agonists, โฆSee details»
Sibia Neurosciences Inc - Company Profile and News
SIBIA Neurosciences, Inc. was acquired and integrated into Merck research laboratories. Sibia's focus was on the development of therapeutics for the treatment of neurodegenerative ...See details»
SIB-1848 - Drug Targets, Indications, Patents - Synapse
SIB-1848: a APP inhibitors Drug, Initially developed by Sibia Neurosciences, Inc., Now, its global highest R&D status is Pending, Mechanism: APP inhibitors(Beta ...See details»
William Comer: interview | Library Digital Collections | UC San โฆ
Jun 20, 2008 He managed the discovery and development of more than 10 blockbuster products. From April 1991 until November 1999 he was President and CEO of SIBIA โฆSee details»
SIBIA Neurosciences - Crunchbase
SIBIA Neurosciences is a Biotechnology company. Start Free Trial . Chrome ExtensionSee details»
Industry Explorers Blaze On: R&D Veteran William Comer Of โฆ
Jul 1, 2015 So he and I started a new company, and we merged it with a Salk development lab in La Jolla to become SIBIA Neurosciences. The people from Salk asked me to be CEO, but I โฆSee details»
Sibia, Lilly Enter $20M Dealm To Develop CNS Therapies
May 27, 1999 Sibia Neurosciences Inc. and Eli Lilly and Co. have teamed up to develop compounds that selectively act on certain subtypes of nicotinic acetylcholine receptors as โฆSee details»
Sibia, Lilly to develop nervous system drugs - MarketWatch
LA JOLLA, Calif. (CBS.MW) -- Shares of Sibia Neurosciences sibi rose after the company said it formed a research partnership with Eli Lilly & Co. to develop...See details»
William T. Comer - Founder, CEO, and Chairman - Crunchbase
Primary Organization . NeuroGenetic Pharmaceuticals . Location Rancho Santa Fe, California, United States; ... From April 1991 until November 1999 he was President and CEO of SIBIA โฆSee details»
Merck & Co to buy Sibia for $87 million - The Pharma Letter
Aug 3, 1999 Merck & Co has agreed to acquire Sibia Neurosciences Inc, the La Jolla,California-based drug producer which focuses on central nervous system disorders. Merck is offering โฆSee details»
SIBIA Neurosciences (SIBI) | Stock Discussion Forums
SIBIA Neurosciences, Inc. is engaged in the discovery and development of novel, small molecule therapeutics for nervous system disorders based on the Company's unique approach to โฆSee details»
SIB-3182 - Drug Targets, Indications, Patents - Synapse
SIB-3182: a Nicotinic receptors agonists Drug, Initially developed by Sibia Neurosciences, Inc., Now, its global highest R&D status is Pending, Mechanism: Nicotinic receptors agonists, โฆSee details»
NBI-112: Drug Targets, Indications, Patents - Synapse
Last update 04 Jul 2023. NBI-112. Last update 04 Jul 2023See details»
Series Introduction: Alzheimerโs disease: perspectives for the new ...
In the next issue of the JCI, Steve Wagner at SIBIA Neurosciences Inc. provides an overview of therapeutic strategies focused on inhibiting Aฮฒ peptide formation by modulating the still ill โฆSee details»
Sibia, Lilly to Develop Compounds for Treatment of CNS Disorders
May 26, 1999 Sibia Neurosciences Inc. is engaged in the discovery and development of novel small molecule therapeutics for the treatment of neurodegenerative, neuropsychiatric ,and โฆSee details»
SIB-1765F - Drug Targets, Indications, Patents - Synapse - Patsnap
Varenicline, a partial alpha4beta2 and full alpha7 nicotinic receptor agonist, has been shown to inhibit nicotine self-administration and nicotine-induced increases in extracellular dopamine in โฆSee details»
SP-650003 - Drug Targets, Indications, Patents - Synapse
Originator Organization. Signal Research Corp. Active Organization-Inactive Organization. Signal Research Corp. Sibia Neurosciences, Inc. Drug Highest Phase Discontinued Discovery. First โฆSee details»